ASCO15: CTI BioPharma Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASC O 2015

Press/Media: Press / Media

PeriodJun 1 2015

Media coverage

1

Media coverage

  • TitleASCO15: CTI BioPharma Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASC O 2015
    Media name/outletBioSpace
    CountryUnited States
    Date6/1/15
    PersonsRuben Mesa